Lucie Nekvindová

6PUBLICATIONS
88CO-AUTHORS
Social epidemiologyPharmacogenomicsRheumatology and arthritisPredictive and prognostic markersRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 06, 2024
Drug survival analysis of etanercept compared with monoclonal antibody tumour necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a propensity score-matched analysis from the Czech ATTRA registry.

Š Tichý, L Nekvindová, J Baranová

|Jun 14, 2023
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries.

Louise Linde, Lykke M Ørnbjerg, Stylianos Georgiadis

|Dec 01, 2022
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment.

Lykke Midtbøll Ørnbjerg, Kathrine Rugbjerg, Stylianos Georgiadis

|Feb 29, 2020
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification.

Jakub Trizuljak, Wolfgang R Sperr, Lucie Nekvindová

|Nov 19, 2019
Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry.

Jan Tužil, Tomáš Mlčoch, Jitka Jirčíková

|Nov 05, 2018
Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study.

Barbora Šumová, Lucie Andrés Cerezo, Lenka Szczuková

Pageof 1

Frequent Collaborators

4 joint publications

Karel Pavelka

3 joint publications

Jiří Vencovský

3 joint publications

Jakub Závada

2 joint publications

Maria José Santos